Migration, invasion, and metastasis are mediated by P-Rex1 in neuroblastoma

被引:2
作者
Jacobson, Jillian C. [1 ]
Qiao, Jingbo [1 ]
Cochran, Elizabeth D. [1 ]
McCreery, Sullivan [1 ]
Chung, Dai H. [1 ]
机构
[1] Univ Texas Southwestern Med Ctr & Childrens Hlth, Dept Surg, Div Pediat Surg, Dallas, TX 75235 USA
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
基金
美国国家卫生研究院;
关键词
neuroblastoma; P-Rex1; migration; invasion; metastasis; CANCER CELL-PROLIFERATION; RAC-GEF; GROWTH; IDENTIFICATION; PREX1; RHO;
D O I
10.3389/fonc.2024.1336031
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neuroblastoma accounts for approximately 15% of pediatric cancer-related deaths despite intensive multimodal therapy. This is due, in part, to high rates of metastatic disease at diagnosis and disease relapse. A better understanding of tumor biology of aggressive, pro-metastatic phenotypes is necessary to develop novel, more effective therapeutics against neuroblastoma. Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 (P-Rex1) has been found to stimulate migration, invasion, and metastasis in several adult malignancies. However, its role in neuroblastoma is currently unknown. In the present study, we found that P-Rex1 is upregulated in pro-metastatic murine models of neuroblastoma, as well as human neuroblastoma metastases. Correspondingly, silencing of P-Rex1 was associated with decreased migration and invasion in vitro. This was associated with decreased AKT-mTOR and ERK2 activity, dysregulation of Rac, and diminished secretion of matrix metalloproteinases. Furthermore, increased P-Rex1 expression was associated with inferior relapse-free and overall survival via tissue microarray and Kaplan-Meier survival analysis of a publicly available clinical database. Together, these findings suggest that P-Rex1 may be a novel therapeutic target and potential prognostic factor in neuroblastoma.
引用
收藏
页数:16
相关论文
共 48 条
[1]   A pan-cancer proteomic perspective on The Cancer Genome Atlas [J].
Akbani, Rehan ;
Ng, Patrick Kwok Shing ;
Werner, Henrica M. J. ;
Shahmoradgoli, Maria ;
Zhang, Fan ;
Ju, Zhenlin ;
Liu, Wenbin ;
Yang, Ji-Yeon ;
Yoshihara, Kosuke ;
Li, Jun ;
Ling, Shiyun ;
Seviour, Elena G. ;
Ram, Prahlad T. ;
Minna, John D. ;
Diao, Lixia ;
Tong, Pan ;
Heymach, John V. ;
Hill, Steven M. ;
Dondelinger, Frank ;
Stadler, Nicolas ;
Byers, Lauren A. ;
Meric-Bernstam, Funda ;
Weinstein, John N. ;
Broom, Bradley M. ;
Verhaak, Roeland G. W. ;
Liang, Han ;
Mukherjee, Sach ;
Lu, Yiling ;
Mills, Gordon B. .
NATURE COMMUNICATIONS, 2014, 5
[2]  
American Cancer Society, Neuroblastoma Survival Rates by Risk Group
[3]  
Barrio-Real Laura, 2018, Oncotarget, V9, P28612, DOI 10.18632/oncotarget.25584
[4]   Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation [J].
Barrio-Real, Laura ;
Benedetti, Lorena G. ;
Engel, Nora ;
Tu, Yaping ;
Cho, Soonweng ;
Sukumar, Saraswati ;
Kazanietz, Marcelo G. .
BREAST CANCER RESEARCH, 2014, 16 (05) :1-13
[5]   Discovery of Small Molecules That Target the Phosphatidylinositol (3,4,5) Trisphosphate (PIP3)-Dependent Rac Exchanger 1 (P-Rex1) PIP3-Binding Site and Inhibit P-Rex1-Dependent Functions in Neutrophils [J].
Cash, Jennifer N. ;
Chandan, Naincy R. ;
Hsu, Alan Y. ;
Sharma, Prateek, V ;
Deng, Qing ;
Smrcka, Alan, V ;
Tesmer, John J. G. .
MOLECULAR PHARMACOLOGY, 2020, 97 (03) :226-236
[6]   Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment [J].
Chantrain, CF ;
Shimada, H ;
Jodele, S ;
Groshen, S ;
Ye, W ;
Shalinsky, DR ;
Werb, Z ;
Coussens, LM ;
DeClerck, YA .
CANCER RESEARCH, 2004, 64 (05) :1675-1686
[7]  
Colon Nadja C, 2011, Adv Pediatr, V58, P297, DOI 10.1016/j.yapd.2011.03.011
[8]   The Rac3 GTPase in Neuronal Development, Neurodevelopmental Disorders, and Cancer [J].
de Curtis, Ivan .
CELLS, 2019, 8 (09)
[9]   Matrix metalloproteinases and tumor metastasis [J].
Deryugina, EI ;
Quigley, JP .
CANCER AND METASTASIS REVIEWS, 2006, 25 (01) :9-34
[10]   P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer [J].
Dillon, L. M. ;
Bean, J. R. ;
Yang, W. ;
Shee, K. ;
Symonds, L. K. ;
Balko, J. M. ;
McDonald, W. H. ;
Liu, S. ;
Gonzalez-Angulo, A. M. ;
Mills, G. B. ;
Arteaga, C. L. ;
Miller, T. W. .
ONCOGENE, 2015, 34 (30) :3968-3976